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IntroductIon
As patients with schizophrenia live longer, 
because of better medical management, 
suicide prevention, and appropriate nutri-
tion, we are beginning to face a new phe-
nomenon: elderly patients with chronic 
schizophrenia developing Alzheimer’s 
disease.
In the past two decades several neuro-
stimulation methods have been introduced 
in psychiatry. These include transcranial 
magnetic stimulation (TMS), vagus nerve 
stimulation (VNS), deep brain stimula-
tion (DBS), and transcranial direct current 
stimulation (tDCS). To date only TMS and 
tDCS have been used in the treatment of 
positive, negative, and cognitive symptoms 
of schizophrenia (1).
These treatment modalities show prom-
ise to decrease the risk of Alzheimer’s disease 
in elderly individuals with schizophrenia, 
but in order to optimize their benefits it is 
essential to recognize the differences in the 
cognitive pathology involved.
Since it is possible that specific neuro-
stimulatory modalities or sites of stimula-
tion affect different regions of the brain or 
domains of neurocognitive pathology in a 
different manner, it is necessary to have a 
better understanding of the cognitive defi-
cits in each condition.
SImIlarItIeS and dIfferenceS 
Between domaInS of cognItIve 
Pathology
In many ways schizophrenia can be consid-
ered as a disease of accelerating aging. It pre-
sents with cognitive deficits and metabolic 
abnormalities. Schizophrenia is associated 
with an increase in mortality, resulting in 
a decrease in average life span of 20% (2).
Patients with schizophrenia show a 
rapid cognitive decline after the age of 65 
in addition to the already existing cogni-
tive deficit. Clinical studies suggest that 
severe cognitive impairment is common 
among elderly patients with schizophrenia 
who reside in long-stay psychiatric institu-
tions (3).
In spite of this data, Alzheimer’s demen-
tia per se is diagnosed in only 9% while 
other dementing diseases are diagnosed 
in 4% of the individuals with schizophre-
nia (4). This finding has led some to the 
assumption that these patients are somehow 
resistant to Alzheimer’s disease.
Despite neurocognitive similarities 
between patients with Alzheimer’s demen-
tia and schizophrenia, there are also major 
neuropsychological as well as laboratory 
differences. In general biological mark-
ers show a lack of increased Alzheimer’s 
pathology in patients with schizophrenia, 
while neuropsychological testing show dif-
ferences in the affected domains of cognitive 
deficits (5).
 neuroPSychologIcal dIfferenceS
The range of cognitive impairments in 
individuals with schizophrenia differs 
from the one in Alzheimer’s disease. In 
elderly schizophrenic individuals there 
is less forgetfulness and delayed recall. 
Most deficits are seen in the processing 
speed, episodic memory, working mem-
ory, and executive function (6). Elderly 
individuals with schizophrenia scored 
lower on digit symbol substitution, pic-
ture completion, and block design in 
Wechsler Adult Intelligence Scale Revised 
(WISE-R) as compared to Alzheimer’s 
disease patients (6).
dIfferenceS In BIologIcal markerS
In post mortem studies, the degree of senile 
plaques or neurofibrillary tangles was not 
different in the schizophrenia group com-
pared with non-schizophrenic psychiatric 
disorders (5).
Amyloid markers
In spite of cognitive deficits, most studies 
failed to find increased amyloid deposits 
in patients with schizophrenia, even after 
age 65, leading to the belief, by some, that 
patients with schizophrenia are protected 
from developing Alzheimer’s disease (6).
Tau pathology markers
Since a more pronounced cognitive decline 
has been described in older schizophrenic 
patients, it has been hypothesized that 
these patients might be at a higher risk of 
developing AD. In spite of this belief, no 
significant differences in CSF total tau and 
phospho-tau levels were found in patients 
with schizophrenia and controls (7).
Functional MRI
Just like different memory domains are 
impaired in schizophrenia vs. Alzheimer’s 
disease, functional MRI shows different 
areas of brain tissue loss in the two con-
ditions. Areas with specifically low gray 
matter volume in AD were distributed 
within the neocortical associative areas, 
while in elderly schizophrenia patients 
these were confined to the posterior part 
of the anterior cingulate gyrus (5). Other 
in vivo neuroimaging studies have pro-
vided evidence of decreases in the gray 
matter volume of the cingulate gyrus in 
subjects with schizophrenia as compared 
to healthy controls (8).
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concluSIon
Elderly individuals with schizophrenia pre-
sent with an accelerating cognitive decline. 
In this respect it is considered as a disease 
of premature aging. DBS was found to be 
beneficial in neurodegenerative disorders 
such as Parkinson’s disease and Alzheimer’s 
disease. TMS has shown benefit in improv-
ing working memory and cognitive symp-
toms in schizophrenia. tDCS was found 
to be beneficial in positive, negative, and 
cognitive symptoms of schizophrenia. 
tDCS stimulation over the left DLPFC has 
been shown to improve executive abilities 
and working memory in individuals with 
dementia. Overall, neurostimulation in 
schizophrenia may be neuroprotective and 
prevent the risk of Alzheimer’s disease.
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IS neuroStImulatIon 
neuroProtectIve?
Neuroprotection is a new direction in 
the treatment of disorders that lead to 
neurodegeneration as a result of deterio-
ration of neurons due to excitotoxicity, 
apoptosis, oxidative stress. The concept 
of neuroprotection has implications for 
mood and cognitive disorders such as 
schizophrenia (9).
Recent studies suggest that neurostim-
ulation may have neuroprotective effects 
(10). For example it is well known that DBS 
of subthalamic nucleus, frequently used in 
treating Parkinson’s disease, was also found 
to be neuroprotective in rats (11).
Deep TMS used primarily for the 
treatment of major depressive disorder, 
was found to have positive effects on 
working memory if applied over the left 
prefrontal cortex (12). In this respect it 
was found beneficial for use in negative 
and cognitive symptoms of schizophre-
nia (13).
Various psychotropic agents used in the 
treatment of schizophrenia and demen-
tia are neuroprotective as well, including 
drugs such as: clozapine (9), quetiapine 
(14), nicotinic agonists, especially alpha 7 
ligands (15), lithium (16, 17), and selec-
tive serotonin uptake inhibitors (SSRI) 
(9). Using neurostimulation as an adjunc-
tive therapeutic technique might aug-
ment the effect of psychotropic drugs by 
offering extra benefit, especially in poor 
responders.
In this respect a recent study showed that 
tDCS provided an alternative and poten-
tially superior approach to the treatment 
of psychotic symptoms in medication-
resistant schizophrenia (18).
Several studies (19–23) showed that 
improvement of cognitive functions was 
promoted by anodal tDCS stimulation. For 
example, stimulation over the left DLPFC 
has been shown to improve executive abili-
ties and working memory performance in 
individuals with dementia (24).
Since gray matter loss in the elderly 
schizophrenia patients was noted in the pos-
terior part of the anterior cingulate gyrus, it 
would be interesting to look at tDCS anodal 
stimulation in that particular area in order 
to prevent development of Alzheimer’s 
dementia in this group.
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